Deepinder Goyal has unveiled six color options for his new health-focused wearable, 'Temple,' with pre-orders expected to open as early as next week. This device, which uses proprietary technology to monitor cerebral blood flow, is a standalone venture-backed startup and operates independently of Zomato.
Deepinder Goyal, the founder of Zomato, has showcased six color variations for 'Temple,' his experimental health-focused wearable device. The confirmed colors are True Gold, Rose Gold, Black Mirror, Real Jade, Deep Blue, and Purple Funk. The announcement signals that the project is nearing its initial commercial rollout, with pre-orders for the launch edition expected to potentially begin as early as next week, subject to final operational readiness.
The Temple wearable is designed to provide continuous monitoring of cerebral blood flow using a proprietary system called 'BrainFlow.' The development team has collaborated with academic researchers from the Indian Institute of Science (IISc) and the Indian Institute of Technology (IIT) Bombay to validate the technology. This experimental device aims to target the premium health-tech segment, with market estimates placing the expected price in the range of Rs 75,000 to Rs 80,000.
It is important for investors to note that Temple is an entirely independent, venture-backed startup and is not part of Zomato (Eternal Ltd). The business operations, financial results, and strategic decisions of Temple are separate from those of Zomato. The company has previously secured approximately $54 million in a seed funding round earlier in 2026, achieving a valuation of roughly $190 million.
While the project is advancing toward a wider release, it remains a new and experimental entry in the wearable technology space. As with any product in the premium health-tech category, the company faces execution risks related to mass production, supply chain management, and long-term market acceptance. Additionally, because the device provides health-related data, it will likely be monitored for its diagnostic precision and regulatory compliance as it moves from development to consumer use.
The primary monitorables for interested users and the industry will be the official opening of pre-orders, confirmed pricing, and subsequent real-world performance reviews. Investors should track these developments as signs of the venture's ability to scale and successfully bring its technology to the broader market.